Daryl Drummond PhD

Dr. Drummond currently serves as the Senior Director of Nanotherapeutics for Merrimack Pharmaceuticals, leads the nanotechnology efforts at Merrimack and was one of the principle inventors for many of Merrimack's nanotechnology-based drugs and platform technologies. MM-398, a nanoliposomal formulation of irinotecan is currently in Phase III clinical trials and MM-302, and ErbB2-targeted pegylated liposomal doxorubicin is currently in Phase I trials in metastatic breast cancer. At Merrimack he leads a broad multidisciplinary team of chemists, biologists, pharmacologists, and biophysicists.

Daryl joined Merrimack in October of 2009 following the merger of Merrimack with Hermes Biosciences. Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics. He later joined Hermes Biosciences in 2000 as an Associate Director of Liposomal Research and Development following a post-doc in the laboratory of the renowned father of current liposome drug delivery systems, Demetrios Papahadjopoulos.